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Triple Reuptake Inhibitors: A Premise and Promise 
 
 
 
On the horizon there is a new class of psychoactive medications which work by inhibiting 
the neuronal reuptake of serotonin, norepinephrine, and dopamine. There are multiple po-
tential indications for these drugs. Research suggests that they may have a role in treating 
depressive disorders, and it is plausible they may have potential efficacy in obesity, addic-
tion, and pain syndromes. The current review describes some of the molecules in develop-
ment presently and explores the research relevant to possible clinical uses for this class of 
medications. 
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Introduction 
 
Prior to the 1980’s, drug candidates were identified by testing laboratory-derived 
compounds in animal models and observing the effects. As biochemical and genetic
research identified the molecular mechanisms that underlie disease, drug development
began to focus on increasing selectivity with the goal of affecting only the target mo-
lecule identified as relevant in order to minimize side effects.
1 
In the past twenty five years, antidepressant drug development followed this trend, 
leading to molecules that specifically inhibit serotonin reuptake (SSRIs) or both sero-
tonin and norepinephrine reuptake (SNRIs). These agents have more benign side effect
profiles than tricyclic antidepressants (TCAs) or monoamine oxidase inhibitors (MAOIs)
owing to a lack of histamine, acetylcholine, and alpha-adrenergic receptor antagonism. 
In short, the selectivity of these newer antidepressants effectively reduced adverse
effects. Although better tolerability was a step forward in the treatment of depression
and other disorders treated with antidepressants, the need remained for agents with im-
proved efficacy and quicker onset of action. SSRIs and SNRIs have not shown advan-
tages in efficacy or in onset of antidepressant response compared to TCAs or MAOIs.
2,3
To date, only 65% of patients treated with antidepressants experience therapeutic res-
ponse,
2-5 and typical onset of action of antidepressants is approximately 2-4 weeks .
6,7
Lately there has been a reversal of the trend towards selectivity in drug develop-
ment across many therapeutic areas. Clinical studies of complex disorders as diverse 
as cancer and schizophrenia reveal that “dirty” drugs affecting a variety of targets tend
to have better efficacy.
1 
Current antidepressant development efforts include the evaluation of triple reup-
take inhibitors which block the reuptake of serotonin, norepinephrine, and dopamine
from the synapse. It is theorized that the additive effect of enhancing neurotrans-
mission in all three monoamine systems (broad spectrum) may lead to improved effi-
cacy and quicker onset of antidepressant response. This review discusses the theory 
behind this development strategy as well as the preclinical and clinical data sup-
porting the potential usefulness of triple reuptake inhibitors for depression and other
disorders.  
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The Triple-Reuptake Premise   
 
Copious evidence links depression to deficiencies in 
neurotransmission of the monoamines serotonin, norepine-
phrine, and dopamine.
8-12 TCAs and MAOIs were seren-
dipitously discovered to be efficacious in depressed patients 
and subsequently became widely used for depression. 
Research since has demonstrated that these medications 
work by inhibiting the norepinephrine and serotonin trans-
porters (e.g. TCAs)
13 and by inhibiting the intracellular 
catabolism of norepinephrine and serotonin (e.g. MAOIs). 
Simultaneously, depletion studies linked depression to de-
ficient amounts of norepinephrine and serotonin
14-16 Ra-
tional drug design later led to SSRIs and SNRIs which 
have successfully led to reduced side effect burden as a 
result of their selectivity for monoamine reuptake sites. 
Other antidepressants have been developed which enhance 
norepinephrine and serotonin neurotransmission via other 
mechanisms; such medications include mirtazepine (pre-
synaptic alpha-2 adrenergic antagonist), as well as trazo-
done and nefazodone (primarily presynaptic and postsy-
naptic 5-HT2 antagonists). Less attention has been given 
to affecting dopamine transmission in depression, althou-
gh data indicate the important role of mesolimbic dopa-
mine in moderating motivation and reward-related be-
havior which are typically disrupted in depression.
17,18 
Furthermore, antidepressants have been shown to sensi-
tize mesolimbic dopamine receptors in animal and human 
studies, findings which have led to the hypothesis that 
enhancing synaptic dopamine availability may lead to 
more rapid antidepressant response.
17 The dopamine and 
norepinephrine reuptake inhibitor bupropion was devel-
oped in the 1980’s as an antidepressant,
19 and it has since 
been repeatedly shown to boost the therapeutic response 
to norepinephrinergic and/or serotonergic antidepressants 
(and decrease sexual side effects) when used as augmen-
tation.
20-22  
Additional data indicate that the stimulant class of medi-
cations, which induce release and block reuptake of dopa-
mine and norepinephrine, augment and hasten antidepres-
sant response when combined with TCA,
23-25 MAOIs,
26,27 
and SSRIs/SRNIs.
28,29 Finally, dopamine agonists them-
selves (bromocriptine, pergolide) have shown efficacy 
as augmenting agents with antidepressants in open label 
studies.
30,31  
Thus, it seems that serotonin, norepinephrine, and do-
pamine systems are all related to the pathophysiology of 
depression and as such are relevant targets for pharma-
cological intervention. This premise has ushered the de-
velopment of medications which enhance neurotrans-
mission of all three systems in an effort to provide more 
reliable efficacy and quicker therapeutic effect. 
The Debate: Is Broader Better? 
 
In a reversal of the move towards selectivity that led 
to the SSRIs in the 1980’s and 1990’s, the SNRIs were 
developed under the premise that a broader spectrum of 
neurotransmitter reuptake inhibition would lead to greater 
antidepressant efficacy and/or more rapid onset of action. 
Data accumulated to date is mixed regarding the useful-
ness of this strategy. With regard to rapidity of onset, 
venlafaxine performed well in a placebo-controlled trial 
in hospitalized depressed patients, demonstrating efficacy 
benefit within one week of treatment initiation.
32 Simi-
larly, venlafaxine produced earlier time to remission of 
depression compared to SSRIs in an open-label trial.
33 A 
meta-analysis of eight studies comparing venlafaxine to 
SSRIs and placebo demonstrates earlier time to remission 
in venlafaxine-treated patients consistently across age and 
gender groups.
34 The authors also cite remission rates of 
45%, 35%, and 25% in patients treated with venlafaxine, 
SSRIs, and placebo respectively, yielding an odds ratio 
for remission of 1.5 favoring venlafaxine over SSRIs.
35 
Two more recent large meta-analyses of studies comparing 
SNRIs to SSRIs revealed a smaller efficacy advantage in 
favor of SNRIs (4.3-5.9% higher remission rate).
36,37 
In these later meta-analyses, the number needed to treat 
(NNT) statistic shows that 17-24 patients would need to 
be treated with SNRIs to yield one additional responder,
36,37 
confronting the notion that SNRIs offer a clinically rele-
vant advantage over SSRIs with respect to likelihood of 
achieving remission of depression. 
Other data endorses the thrust towards increased neu-
rotransmitter selectivity. In particular, a meta-analysis of 
the highly selective SSRI escitalopram (S-isomer of ci-
talopram) suggests that this medication is superior in effi-
cacy to other SSRIs and to the SNRI venlafaxine (grouped 
together) on the outcomes of response rate, remission rate, 
and overall treatment outcome.
38 A second meta-analysis 
indicates more rapid onset of action of escitalopram com-
pared to other SSRIs and venlafaxine extended-release 
(grouped together).
39 Thus, it remains controversial whe-
ther certain antidepressants confer clinically relevant ad-
vantages in rapidity of onset or overall efficacy for de-
pression, and whether such differences are related to the 
breadth of their neurotransmitter reuptake inhibition.   
It should also be noted that currently available dual 
reuptake inhibitors differ in their relative potencies at 
monoamine transporters. Milnacipran blocks serotonin 
and norepinephrine reuptake equally, whereas greater se-
lectivity at serotonin reuptake sites is characteristic of 
venlafaxine (30-fold) and duloxetine (10-fold).
40 Clini-
cal ramifications of these differences in selectivity are 
poorly understood.    
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Compounds in Development 
 
Despite the structural similarity of the norepinephrine, 
serotonin, and dopamine transporters, synthesis of bio-
available and safe molecules which appreciably inhibit 
all three transporters has been challenging.
41 Addition-
ally, the optimal selectivity at the three transporter sites 
is unknown, and it is plausible that different potency ra-
tios mean different clinical effects. Two families of com-
pounds in development are analogs of the dual reuptake 
inhibitors milnacipran and venlafaxine. Several milna-
cipran derivatives have been developed in search of 
molecules with more potent N-methyl-D-aspartic acid 
(NMDA) antagonism.
42,43 More recently, analogs have 
been synthesized to evaluate their relative monoamine 
transporter inhibition potency and selectivity. An isomer 
of one such analog (-)-8h functions as a triple reuptake 
inhibitor in vitro.
40 To date, animal or human antidepres-
sant studies have not been published with this compound. 
Racemic analogs of venlafaxine referred to as PRC025 
and PRC050 are highly potent at human norepinephrine 
(NE), serotonin (SER), and dopamine (DA) transporters 
and inhibit the reuptake of these monoamines into rat brain 
synaptosomes.
4 These compounds exhibited antidepres-
sant-like characteristics equal to imipramine in well-ac-
cepted rat models of antidepressant effect; both PRC025 
and PRC050 increased time spent swimming and reduced 
time spent immobile in the forced swim test and reduced 
time spent immobile in the tail suspension test .
4  
DOV Pharmaceuticals has developed triple reuptake 
inhibitors from a class of azabicyclohexanes chemically 
related to bicifadine. Three of these compounds (DOV 
216,303, DOV 21,947, and DOV 102,677) have been 
shown to block transport of human recombinant NE, SER, 
and DA transporters with clinically-relevant potency 
(Table 1).
8,17,44,45 Also, all three of these compounds 
demonstrated antidepressant properties in rodent models; 
21,947 reduced immobility during forced swim test and 
tail suspension test,
44 102,677 reduced immobility during 
forced swim test,
8 and 216,303 reduced immobility dur-
ing forced swim test and reversed tetrabenazine-induced 
ptosis.
17 Human studies with DOV 216,303 show that it 
is well-tolerated at clinically appropriate doses with minor 
gastrointestinal side effects ranging from 19-57%.
17,45 
A small citalopram-controlled clinical trial of DOV 
216,303  (n=67) yielded significant improvements in 
Hamilton Depression Rating Scale (HAM-D) scores in 
both groups at both the one-week and two-week time 
points, although the study lacked a placebo group.
17 Bi-
cifadine (1-p-tolyl-3-azabicyclo[3.1.0]hexane) itself has 
been pharmacologically characterized, and it has been 
shown to inhibit monoamine neurotransmitter uptake by 
recombinant human transporters in vitro with a relative 
potency of norepinephrine：serotonin：dopamine of 1：
2：17.
46 To date, published preclinical research has 
focused on the potential antinociceptive properties of bi-
cifadine,
46 although its utility as an antidepressant war-
rants exploration. 
The novel triple reuptake inhibitor tesofensine (NS 
2330) has not been systematically studied regarding its 
clinical or preclinical antidepressant effects. Similar to 
antidepressants,
47 this agent has demonstrated neuropro-
tective effects including increasing brain derived neuro-
trophic factor (BDNF) and neuronal proliferation in the 
rat hippocampus.
48  
Presumably other triple reuptake inhibitors are in va-
rious developmental phases, and the current discussion 
of compounds in development should not be considered 
exhaustive. A summary of described compounds appears 
below in Table 1.   
 
Other Potential Indications 
for Triple Reuptake Inhibitors 
 
Like other classes of antidepressant medications, tri-
ple reuptake inhibitors likely hold promise for a variety 
of therapeutic indications. One emerging area of research 
concerns the potential antinociceptive effects of triple in-
hibitors, which is expected given the copious data sup-
porting the utility of TCAs and SNRIs for pain syndromes. 
Preclinical research with bicifadine demonstrates its an-
tinociceptive effects in animal models of acute, persistent, 
and chronic pain including inflammatory, visceral, and 
nociceptive paradigms. These effects were reduced in 
some experimental conditions by the coadminstration of 
sulpride (a dopamine-2 receptor antagonist), suggesting 
that enhancement of dopamine neurotransmission is im-
portant for the full antinociceptive effect of bicifadine.
46 
One published preclinical study describes the effect 
of the “balanced” triple reuptake inhibitor DOV 102,677 
in reducing volitional alcohol consumption in ethanol-
preferring rats without decreasing food or water consump-
tion.
49 It should be noted that monoamine reuptake in-
hibitors have historically performed better in animal 
models of addiction than in human clinical trials. However, 
it is possible that agents which inhibit dopamine reup-
take may offer improved efficacy in addictive disorders 
due to the link between dopamine and reward-motivated 
behaviors. Subsequent clinical trials in subjects with ad-
dictive disorders will elucidate the potential for triple 
reuptake inhibitors to reduce addictive behaviors.   
The prodopaminergic potential of tesofensine led to a 
proof-of-concept study of this agent in the treatment of 
Parkinson’s disease (PD). In this adequately-powered  
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study (n=261) with multiple dosage arms correspond-
ing to up to 77% dopamine transporter occupancy, teso-
fensine did not outperform placebo.
50 Two smaller open-
label studies of tesofensine and the related compound 
brasofensine also failed to demonstrate benefit in PD.
51,52 
One possible explanation is homeostatic reduction in do-
pamine synthesis and release.
50 In contrast, in a phase 
IIa pilot study in Alzheimer’s disease, tesofensine treat-
ment was associated with cognitive improvements;
51 the 
physiological mechanism of this observation is unclear, 
although it has been proposed that tesofensine indirectly 
stimulates cholinergic neurotransmission.
51 
Weight loss has been observed as an adverse event in 
studies of tesofensine,
50 prompting further research for 
the indication of obesity. The pharmaceutical company 
Neurosearch has conducted a phase IIb proof-of-concept 
dose-finding study and a subsequent study of metabolic 
outcomes using tesofensine; both of these studies indi-
cate that tesofensine is efficacious in promoting weight 
loss in obese subjects.
53 The triple reuptake inhibitor si-
butramine is approved by the United States Food and 
Drug Administration (FDA) for the indication of obe-
sity. Research is generally lacking regarding the antide-
pressant potential of sibutramine, although a small study 
in obese and overweight subjects (n=60) suggests that 
it has mood-enhancing effects.
54 
 
Discussion 
 
The impetus to develop triple reuptake inhibitors is a 
natural consequence of the rich drug development his-
tory occurring over the past fifty years. We have come a 
long way since the serendipitous discovery that TCAs 
and MAOIs exert antidepressant effects. Rational drug 
design has allowed us to customize the receptor profiles 
of potential antidepressant drugs and to target specific 
monoamine reuptake transporters. Current strategies in-
volve developing multiple analogues of dual reuptake in-
hibitors and characterizing their receptor profiles in or-
der to develop a quiver of molecules with clinically-re-
TABLE 1. Characteristics and pharmacokinetic parameters of triple reuptake inhibitors in development
Products Compounds  Origin 
Evidence of 
antidepressant 
potential 
Affinity 
Ki (nm/L) 
NE：SER：DAa 
Potency 
IC50 (nM) 
NE：SER：DAa 
Half- 
life 
(hr) 
Tmax 
(Time to peak 
concentration 
in hrs) 
(-)-8h  (-)-(1R,2S)-naphthyl 
  derivative of milnacipran 
 None    5：18：140    
PRC025  (2SR,3RS)-N,N-dimethyl-3- 
cyclohexyl-3-hydroxy-2- 
(2′-naphthyl)propylamine 
Racemic 
 analogue  of 
venlafaxine 
Animal/ 
Preclinical 
 
10：6：53      
PRC050  (2RS,3RS)-N-methyl-3- 
hydroxy-2-(2′-naphthyl)-3- 
phenylpropylamine 
Racemic 
 analogue  of 
venlafaxine 
Animal/ 
Preclinical 
 
1.2：12：43      
DOV 216,303  [(±)-1-(3,4-dichlorophenyl)- 
3-azabicyclo-[3.1.0] 
hexane 
hydrochloride] 
 Animal/ 
Preclinical 
Small human 
 clinical  trial 
  (not placebo- 
controlled) 
 
 21：14：78 Approx. 
3.3 to 
4.4 
Approx. 1 
DOV 21,947  [(+)-1-(3,4-dichlorophenyl)- 
3-azabicyclo-[3.1.0]  
hexane hydrochloride] 
(+)-enantiomer 
of 
DOV 216,303 
Animal/ 
Preclinical 
 
262：99：213 23：12：96    
DOV 102,677  [(–)-1-(3,4-dichlorophenyl)- 
3-azabicyclo-[3.1.0] 
hexane 
hydrochloride]) 
(-)-enantiomer 
of 
DOV 216,303 
Animal/ 
Preclinical 
 
1030：740：222 103：133：129    
Bicifadine  (+/-)-1-(4-methylphenyl)- 
3-azabicyclo-[3.1.0] 
hexane HCl)] 
DOV 220,075  None  5.0：2.4：5.2 
(μM) 
55：117：910 Approx. 
3.5 
Approx. 1 
Tesofensine 
(NS2330) 
8-azabicyclo[3.2.1]octane, 
3-(3,4-dichlorophenyl)- 
2-(ethoxymethyl)-8- 
methyl-,[1R-(2-endo, 
3-exo)]-,2-hydroxy-1,2,3- 
propanetricarboxylate 
 None    1.7：11：65 Approx. 
230 
Approx. 6-8 
IC50: concentration required for 50% inhibition in vitro, Ki: binding affinity of the inhibitor, NE：SE：DA=Norepinephrine：Serotonin：Do-
pamine 
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levant activity at all three monoamine reuptake sites. 
The ideal ratio of transporter site potencies that a triple 
reuptake inhibitor should exhibit remains unknown, and 
hopefully the diversity of molecules in development will 
shed light on this issue. Future research will undoubt-
edly involve clinical study of various triple reuptake 
inhibitors to determine whether any of them offer advan-
tages over currently approved antidepressants in efficacy, 
rapidity of onset, or side effect profile. Research pub-
lished to date tends to support that antidepressants vary 
modestly in various outcomes related to efficacy. Yet, 
findings are mixed regarding whether broader spectrum 
agents or highly serotonin-selective agents confer the 
best efficacy for depression, although the argument in 
favor of broader spectrum agents is more believable. St-
ronger evidence for superiority of broad spectrum agents 
appears in research on various pain syndromes such as 
fibromyalgia and headache; TCAs and SNRIs have 
shown more consistent benefit than SSRIs,
55,56 possibly 
related to serotonin’s propensity to both facilitate and 
inhibit pain in contrast to norepinephrine which is purely 
antinociceptive. The role of dopamine in pain proces-
sing is less established, although preclinical evidence 
suggests that dopaminergic neurotransmission in the nu-
cleus accumbens at least partially mediates the antino-
ciceptive property of nitrous oxide.
57 Thus, triple reuptake 
inhibitors may have a clinical role in the treatment of 
pain syndromes as demonstrated by bicifadine data.
47 
Of note, concern has been expressed that triple re-
uptake inhibitors may produce broader side effect burden 
without enhancing efficacy over more selective agents.
58 
In actuality, it is plausible that triple reuptake inhibitors 
that minimize blockade at histaminergic, cholinergic, and 
alpha-adrenergic receptors may yield the most favorable 
tolerability of all antidepressants with less sexual side 
effects than SSRIs or SNRIs. By way of example, bu-
propion has long been used to treat antidepressant-related 
sexual dysfunction, presumably through its dopaminer-
gic effects.
19 Many of these questions will be answered 
by subsequent research.   
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